AEterna Zentaris (TSX:AEZS) EBIT per Share : C$-5.00 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris EBIT per Share?

AEterna Zentaris's EBIT per Share for the three months ended in Dec. 2023 was C$-1.77. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$-5.00.

During the past 3 years, the average EBIT per Share Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for AEterna Zentaris's EBIT per Share or its related term are showing as below:

TSX:AEZS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -73.1 Med: 18.2 Max: 69.8
Current: -1.7

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of AEterna Zentaris was 69.80% per year. The lowest was -73.10% per year. And the median was 18.20% per year.

TSX:AEZS's 3-Year EBIT Growth Rate is ranked worse than
55.94% of 1305 companies
in the Biotechnology industry
Industry Median: 3.2 vs TSX:AEZS: -1.70

AEterna Zentaris's EBIT for the three months ended in Dec. 2023 was C$-8.58 Mil.

AEterna Zentaris EBIT per Share Historical Data

The historical data trend for AEterna Zentaris's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris EBIT per Share Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-17.95

-3.11

-2.41

-4.27

-4.98

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-1.12	-1.19	-0.78	-1.27	-1.77

AEterna Zentaris EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

AEterna Zentaris's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.16	/	4.856
=	-4.98

AEterna Zentaris's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-8.581	/	4.858
=	-1.77

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-5.00

AEterna Zentaris (TSX:AEZS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

AEterna Zentaris EBIT per Share Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.